Clinical Trial

RSV Vaccine in Transplant Recipients

Study acronym: RSVax
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-09-09; most recent amendment 2026-04-27.
Status change: Recruiting → Active, Not Recruiting 2026-04-27
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06593210
Lead Sponsor University Health Network, Toronto
Collaborators: University of British Columbia, The Physicians' Services Incorporated Foundation
Conditions Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
Enrollment 100 participants
Start Date 2024-10-01
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-01